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Introduction {#sec005}
============

Since their first introduction in the 1950s, antipsychotic medications have been used to treat a growing array of conditions. While first approved as treatment for schizophrenia \[[@pone.0163796.ref001]\], their use has rapidly extended to other disorders. Currently, FDA-approved uses of typical antipsychotics include schizophrenia, bipolar disorder, psychotic disorders in general, agitation, hyperactivity, Tourette syndrome, generalized nonpsychotic anxiety, and severe behavioural problems \[[@pone.0163796.ref002]\]. The applicability of these drugs increased only further with the introduction of atypical antipsychotics \[[@pone.0163796.ref003]\]. These are now approved to treat conditions that range from autism to major depressive disorder (MDD) \[[@pone.0163796.ref004]\].

Nonetheless, off label use of antipsychotic drugs is still an extended practice. Prescribing antipsychotic drugs to treat unapproved conditions and employing excessive doses are two of the most common examples. In particular, antipsychotics have been regularly used to treat behavioural symptoms in elderly patients with dementia, despite conflicting evidence to support it \[[@pone.0163796.ref005]\]. In fact, the percentage of patients with FDA-unapproved disorders taking antipsychotics in the US has been estimated to range from 60% to 83% \[[@pone.0163796.ref006],[@pone.0163796.ref007]\], with an estimated cost in 2008 of \$6.0 billion \[[@pone.0163796.ref006]\].

Finally, many patients are treated with two or more antipsychotic drugs in combination, although its effectiveness remains to be demonstrated \[[@pone.0163796.ref008],[@pone.0163796.ref009]\]. Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient \[[@pone.0163796.ref010]\]. In outpatient settings, antipsychotic polypharmacy is somewhat less frequent when compared to inpatient populations, possibly due to lesser illness severity. However, in a large cohort in the US consisting of outpatients from three different health care settings, Sun et al. \[[@pone.0163796.ref011]\] reported that approximately one fifth of those with psychotic disorders were under a treatment schedule consisting of more than one antipsychotic drug. In Canada, Procyshyn et al. \[[@pone.0163796.ref012]\] reported an antipsychotic polypharmacy prevalence of 25.7% in outpatients. Furthermore, in a European outpatient setting, Novick et al. \[[@pone.0163796.ref009]\] reported polypharmacy in approximately one third of the patients, with a tendency for a slight increase during a one year follow up. A recent review further reported that among adults, off label prescription consisted of 40 to 75% of all antipsychotic prescriptions \[[@pone.0163796.ref013]\]. Antipsychotic polypharmacy is common. Evidence of efficacy however, is limited to small randomized controlled clinical trials, case reports, and individual clinician experience. At the same time, antipsychotic polypharmacy has been associated with an increased risk of metabolic syndrome \[[@pone.0163796.ref014]\], higher healthcare costs \[[@pone.0163796.ref015]\], and possibly mortality \[[@pone.0163796.ref016]\].

Over the last decade, medical prescription security has been supported by the emergence of electronic health records (EHRs) and clinical decision support systems (CDSS) that facilitate portability and processing of pertinent health information related to pharmacological treatment \[[@pone.0163796.ref017]\]. This has helped monitor prescription patterns that include off label use, polypharmacy and high dosage. Inter-institutional EHRs are used to further increase efficiency in medical services and provide complete and accurate medical information across providers in different institutions \[[@pone.0163796.ref018]\]. CDSS are made possible by digitalization of clinical data. Their purpose is to improve clinical management, methodological contributions, sensitivity and simulation tools in order to evaluate the clinical impact of the prescription decisions. The emergence of electronic prescribing devices with decision support systems significantly reduces error rates \[[@pone.0163796.ref019]\]. They also reveal an important source of epidemiological insight about how treatment is prescribed and taken, although these are extremely expensive and are not widely implemented. However, current EHRs often fall short of delivering readily available, compiled and tailored medical knowledge regarding the patient to the clinician \[[@pone.0163796.ref020]\]. The availability of handheld computing provides the opportunity to implement many of these gains to institutions where e-prescribing systems are not yet accessible. The increasing availability of smartphone technology permits the gathering of naturalistic data that can be processed immediately and provide instantaneous decision making assistance to clinicians.

A pioneer project in the 1980s programmed drug monitoring systems to identify evidence-based medication practices in 11 New York State Institutions for Mental Health and Developmental Disabilities. The results of the study showed that the surveillance techniques improved prescribing practices \[[@pone.0163796.ref021]\]. EHRs are now used routinely and are a major source of structured data. In a naturalistic, observational, retrospective, non-interventional study, Gavirina et al. \[[@pone.0163796.ref022]\] were able to describe prescription habits in a sample of 1700 patients suffering from schizophrenia. The data were gathered from computerized or e-medical records that were registered in the electronic medical record and implemented in all centers of the network that performed the assessment.

However, these systems present some limits that are related to the methodology of such studies; observational studies based on retrospective analysis of EHR data. For example routine practice data are collected for billing or institutional purposes. The re-use of these data to advance clinical research can be challenging \[[@pone.0163796.ref023]\]. The timing, quality, and comprehensiveness of clinical data are often not consistent with research standards \[[@pone.0163796.ref024]\]. Accuracy (correctness) of data relies on correct and careful documentation, which is often difficult to perform though most EHR used in routine. Furthermore, due to the architecture of traditional EHR, data cannot be processed instantaneously to deliver a CDSS, which requires a double task of de-identification of the data, and statistical analysis out of the software core. Most studies describing antipsychotic habits use retrospective methods \[[@pone.0163796.ref025]\]. By doing so, researchers and clinicians miss the opportunity to process gathered data in the moment and use them for CDSS purposes. The use of electronic records for decision support at a clinical level is still not widely reported. EHRs are usually commercial software only accessible from computers having wired connection. This characteristic excludes systematic assessment of outpatients that are treated by primary care services or those that are hospitalized out of the mainstream care services.

Taking into consideration the strengths and pitfalls of each of these monitoring strategies, we developed a web application that is able to adapt to any common routine follow-up strategy and research protocol in medicine. The growth and popularity of mHealth apps (health-related software applications), their ease of use and their cost of development compared to traditional software make them particularly suitable for the task of prescription monitoring.

Our Hypothesis was that a web application developed for this study may be able to describe clinician prescriptions. The objective of this study was to describe, via the Memind web-application, the prescription patterns of antipsychotics in a naturalistic outpatient setting in five Psychiatric Community Mental Health Centers in Madrid, Spain. We focused primarily on off label uses and antipsychotic polypharmacy.

Materials and Methods {#sec006}
=====================

Study setting {#sec007}
-------------

Four thousand nine hundred and seventy-five patients received psychiatric care in five Psychiatric Community Mental Health Centers (Moncloa Mental Health Center, Arganzuela Mental Health Center, Infanta Elena Hospital, Valdemoro Mostoles Hospital, Hospital 12 de Octubre Hospital) part of the Psychiatry Department of Fundacion Jimenez Diaz in Madrid, Spain, during the study period (from June 2014 to October 2014). This department is part of the National Health Service and provides medical coverage financed by taxes to a catchment area of 800,000 people. Fifty-five clinicians of the Memind study group participated in the patient recruitment process. Outpatients were assessed during routine medical visit by these clinicians. The clinician also created a profile in the MEmind web application for each patient that met the inclusion criteria and agreed to participate.

Patient inclusion and exclusion criteria {#sec008}
----------------------------------------

Inclusion criteria were either male or female outpatients, aged 18 or older, who gave written informed consent. Participants were excluded from the study if they were under the age of 18, incarcerated, under guardianship, enrolled in other trials, or were in emergency situations where their state of health did not allow for obtaining written informed consent.

Material {#sec009}
--------

The web application was specifically developed for Android and OSX Smartphones, Tablets and the Mac and PC versions of Mozilla firefox and Google Chrome. It is available in three languages (English, French, Spanish). The web application has two distinct interfaces. The "electronic health record" view is designed for use by health care providers during clinical rounds and medical or nursing visits. It has been designed to cover all the data acquired during a standard psychiatric evaluation, including sociodemographic, diagnostic and pharmacological treatment information. Furthermore, it is based on commonly stored information in mental health management. A large customizable choice of relevant scales can be added by the care provider to the basic evaluation. The patient view was also developed and will allow patients to be monitored with ecological momentary assessment (EMA) tools in future studies. Patient had no access to this function for the present study.

Three different user profiles exist: 1) for patients; 2) for caregivers/family; and 3) for mental health professionals. For the purposes of this study we only used the mental health professional profile ([Fig 1](#pone.0163796.g001){ref-type="fig"}). During this study, patients did not have access to the web application. If they agreed to participate to the study, they only agreed to allow their clinician to enter their personal data into the MEmind web application. The patients were still treated as usual.

![The MEmind web application as viewed from an OSX tablet.](pone.0163796.g001){#pone.0163796.g001}

Each patient was identified by a numeric code that ensures patient anonymity. This code is encrypted in the database that remained the same throughout all contact with patients cared for during the study.

Baseline assessment {#sec010}
-------------------

For this study, variables collected for each patient profile were sex, age, diagnosis and treatment. Clinical diagnoses were made by psychiatrists or clinical psychologists, coded according to the ICD-10 \[[@pone.0163796.ref026]\] for mental disorders, and entered manually into the MEmind web-application. Diagnoses were assigned by the clinician, not automatically done by the application. Allocation of information was done by the clinician via the clinician interface of the web application.

Outcomes measures {#sec011}
-----------------

Pharmacological treatment was registered with our web tool and then classified according to the Anatomical Therapeutic Chemical (ATC) classification system and the defined daily dose (DDD)\[[@pone.0163796.ref027]\]. We calculated the average of daily dose prescribed for antipsychotics (N05A ATC code), Prescribed Daily Dose (PDD), and the PDD to DDD ratio. Although ATC classification includes lithium and antipsychotics under the N05A code, for the purpose of this study we only included antipsychotics. In order to compare dosages of the various antipsychotics we used a fixed unit of measurement based on dividing the prescribed daily dose (PDD) by the defined daily dose (DDD). A PDD/DDD ratio greater than 1.5 was defined as excessive dosing \[[@pone.0163796.ref012]\]. We performed double verification of the results using the SSPS version 22.0 package.

Ethical considerations {#sec012}
----------------------

The research was in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the Institutional Review Board and granting agency. All the participants provided written informed consent, after the complete description of the study. Previously, the research protocol was approved by the local (Fundacion Jimenez Diaz) Ethics Committee.

Results {#sec013}
=======

Diagnoses and sample characteristics {#sec014}
------------------------------------

Out of the 4975 outpatients that received psychiatric care during study period, 4345 agreed to participate to the study. The distribution of psychiatric disorders attended in our outpatient units is shown in [Table 1](#pone.0163796.t001){ref-type="table"}, and the distribution of the most common disorders according to age and gender is shown in [Table 2](#pone.0163796.t002){ref-type="table"}.

10.1371/journal.pone.0163796.t001

###### Prevalence of psychiatric disorders (n = 4975).
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  Psychiatric disorder                                                                                    N (4975)   \%
  ------------------------------------------------------------------------------------------------------- ---------- ------
  F0-F09 Organic, including symptomatic, mental disorders                                                 85         2.0
  F10-F19 Mental and behavioural disorders due to psychoactive substance use                              314        7.2
  F20-F29 Schizophrenia, schizotypal and delusional disorders                                             574        13.2
  F30-F39 Mood \[affective\] disorders                                                                    1221       28.1
  F40-F48 Neurotic, stress-related and somatoform disorders                                               1956       45.0
  F50-F59 Behavioural syndromes associated with physiological disturbances and physical factors           176        4.1
  F60-F69 Disorders of adult personality and behaviour                                                    475        10.9
  F70-F79 Mental retardation                                                                              41         0.9
  F80-F89 Disorders of psychological development                                                          10         0.2
  F90-F98 Behavioural and emotional disorders with onset usually occurring in childhood and adolescence   74         1.7
  F99-F99 Unspecified mental disorder                                                                     49         1.1

10.1371/journal.pone.0163796.t002

###### Age and gender distribution of most common psychiatric disorders (n = 4354).
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                                Schizophrenia and other psychoses (n = 574; 13.2%)   Mood disorders (n = 1221; 28.1%)   Neurotic. stress related and somatoform disorders (n = 1956; 45.0%)   Personality disorder (n = 475; 10.9%)   Total (n = 4345)
  -------------- -------------- ---------------------------------------------------- ---------------------------------- --------------------------------------------------------------------- --------------------------------------- ------------------
  Age n (%)      18--35 years   132 (23%)                                            146 (12%)                          424 (21.7%)                                                           114 (24.1%)                             890 (20.5%)
  35--50 years   232 (40.5%)    329 (27%)                                            733 (37.5%)                        208 (43.6%)                                                           1517 (34.9%)                            
  50--65 years   160 (27.8%)    446 (36.5%)                                          561 (28.7%)                        119 (25.1%)                                                           1304 (30%)                              
  \>65 years     50 (8.6%)      300 (24.5%)                                          238 (12.2%)                        35 (7.3%)                                                             634 (14.6%)                             
                 p-value        \<0.001                                              \<0.001                            \<0.001                                                               \<0.001                                 
  Gender n (%)   Female         377 (65.6%)                                          855 (70.0%)                        1330 (68.0%)                                                          275 (57.9%)                             1621 (62%)
  Male           197 (34.4%)    366 (30.0%)                                          626 (32.0%)                        200 (42.1%)                                                           2724 (37.3%)                            
                 p-value        \<0.001                                              \<0.001                            \<0.001                                                               0.024                                   

Out of our total sample, 3640 patients had one psychiatric diagnosis, with anxiety and related disorders (F40-F49) being the more frequent diagnoses. The rest of the patients showed a co-morbid condition. Antipsychotics were used in 1116 patients (25% of total patients), 829 (74%) in monotherapy and 287 (26%) in poly-therapy (for detail see [Table 3](#pone.0163796.t003){ref-type="table"}).

10.1371/journal.pone.0163796.t003

###### Antipsychotic monotherapy and polypharmacy according diagnosis (n = 1116).
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  Diagnosis       Patient with specific diagnostic N (%)   Antipsychotic use   Antipsychotic monotherapy   Antipsychotic polypharmacy   
  --------------- ---------------------------------------- ------------------- --------------------------- ---------------------------- ------------
  One diagnosis   F0-F09                                   44 (1.0%)           26 (2.3%)                   23 (2.8%)                    3 (1%)
  F10-F19         111 (2.6%)                               26 (2.3%)           24 (2.9%)                   2 (0.7%)                     
  F20-F29         476 (11.0%)                              462 (41.4%)         305 (36.8%)                 157 (54.7%)                  
  F30-F39         966 (22.2%)                              268 (24%)           204 (24.6%)                 64 (22.2%)                   
  F40-F49         1630 (37.5%)                             82 (7.3%)           78 (9.4%)                   4 (1.4%)                     
  F50-F59         101 (2.3%)                               9 (0.8%)            9 (1.1%)                    0 (0%)                       
  F60-F69         203 (4.7%)                               69 (6.1%)           60 (7.2%)                   9 (3.1%)                     
  F70-F79         22 (0.5%)                                13 (1.2%)           9 (1.1%)                    4 (1.4%)                     
  F90-F99         87 (2%)                                  7 (0.62%)           7 (0.8%)                    0 (0%)                       
  Comorbidity     F0-F09 + F30-F39                         15 (0.3%)           11 (1%)                     8 (1%)                       3 (1.0%)
                  F10-F19 + F20-F29                        23 (0.5%)           23 (2%)                     11 (1.3%)                    12 (4.2%)
                  F10-F19 + F30-F39                        33 (0.8%)           12 (1%)                     8 (1%)                       4 (1.4%)
                  F10-F19 + F40-F49                        36 (0.8%)           5 (0.4%)                    5 (0.6%)                     0 (0%)
                  F10-F19 + F60-F69                        23 (0.5%)           9 (0.8%)                    7 (0.8%)                     2 (0.7%)
                  F20-F29 + F40-F49                        13 (0.3%)           12 (1%)                     10 (1.2%)                    2 (0.7%)
                  F20-F29 + F60-F69                        13 (0.3%)           12 (1%)                     6 (0.7%)                     6 (2.1%)
                  F30-F39 + F40-F49                        47 (1.1%)           8 (0.7%)                    6 (0.7%)                     2 (0.7%)
                  F30-F39 + F50-F59                        17 (0.4%)           1 (0.1%)                    0 (0%)                       1 (0.3%)
                  F30-F39 + F60-F69                        83 (1.9%)           32 (2.9%)                   22 (2.7%)                    10 (3.5%)
                  F40-F49 + F40-F49                        73 (1.7%)           10 (0.9%)                   10 (1.2%)                    0 (0%)
                  F40-F49 + F50-F59                        32 (0.7%)           1 (0.1%)                    1 (0.1%)                     0 (0%)
                  F40-F49 + F60-F69                        73 (1.7%)           18 (1.6%)                   16 (1.9%)                    2 (0.7%)
                  Other combinations                       224 (5.2%)          0 (0%)                      0 (0%)                       0 (0%)
                  TOTAL                                    4345                1116 (26%)                  829 (19%)                    287 (6.6%)

Antipsychotic pattern use {#sec015}
-------------------------

Concerning diagnoses, as a simple diagnosis or comorbidity, out of the 1116 patients in which antipsychotics were prescribed, 44% of them (486 patients) were used in patients with schizophrenia and related disorders, 28% (309 patients) in affective disorders, 13% (140 patients) in personality disorders, and 136 (12%) in anxiety and related disorders. It is interesting to note that 14 patients with schizophrenia and related disorders did not receive antipsychotics ([Table 3](#pone.0163796.t003){ref-type="table"}).

Out of the 1116 patients using antipsychotics, 1475 antipsychotic prescriptions were made. Out of the 829 patients (74%) using an antipsychotic as a monotherapy, antipsychotics were the only therapy used for 185 (185/829, 22%) of them. The most common combination of antipsychotics with another psychotropic drug was with antidepressants (in 109 patients). Antipsychotics were used in polypharmacy regimen in 287 patients (26%). In 151 patients, the combinations were only used with other antipsychotics.

[Table 4](#pone.0163796.t004){ref-type="table"} shows the different antipsychotics prescribed, ATC/DDD classification and doses employed in our clinical practice. It is important to note that antipsychotics used in an excessive dosing were long-acting paliperidone and ziprasidone.

10.1371/journal.pone.0163796.t004

###### Prescribed Daily Dose (PDD), and the PDD to defined daily dose ratio of antipsychotics (n = 1116).
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  Number of prescriptions   Drug                       ATC code   DD (mg)   Median PDD (mg)   Mean PDD (mg)   PDD (mg) IC 95%   PDD/DDD
  ------------------------- -------------------------- ---------- --------- ----------------- --------------- ----------------- ---------
  47                        Amisulpride                N05AL05    400       400.00            520.21          401.63--638.79    1.30
  262                       Aripiprazole               N05AX12    15        10.00             12.76           11.68--13.84      0.85
  88                        Asenapine                  N05AH05    20        7.50              9.29            8.07--10.51       0.46
  3                         Chlorpromazine             N05AA01    300       100.00            76.67           30.93--122.40     0.26
  24                        Clotiapine                 N05AH06    80        40.00             37.20           31.71--42.69      0.47
  65                        Clozapine                  N05AH02    300       280.00            287.92          254.42--321.43    0.96
  16                        Fluphenazine               N05AB02    1         0.89              0.89            0.72--1.05        0.89
  25                        Haloperidol                N05AD01    8         5.00              6.96            4.36--9.55        0.87
  13                        Levomepromazine            N05AA01    300       38.75             63.61           41.46--85.76      0.21
  1                         Levosulpiride              N05AL07    400       25.00             25.00                             0.06
  150                       Olanzapine                 N05AH03    10        10.00             9.82            8.66--10.98       0.98
  104                       Paliperidone               N05AX13    6         6.00              7.56            6.61--8.50        1.26
  214                       Long-acting paliperidone   N05AX13    2,5       3.57              4.41            4.17--4.65        1.76
  1                         Perphenazine               N05AB03    30        8.00              8.00                              0.27
  3                         Pimozide                   N05AG02    4         4.00              3.67            0.82--6.51        0.92
  279                       Quetiapine                 N05AH04    400       100.00            194.35          170.76--217.95    0.49
  110                       Risperidone                N05AX08    5         3.00              4.15            3.51--4.79        0.83
  5                         Long-acting risperidone    N05AX08    2,7       3.57              3.57            1.65--5.49        1.32
  1                         Sertindole                 N05AE03    16        4.00              4.00                              0.25
  2                         Sulpiride                  N05AL01    800       100.00            100.00                            0.13
  19                        Tiapride                   N05AL03    400       100.00            144.74          107.34--182.13    0.36
  14                        Ziprasidone                N05AE04    80        90.00             130.00          72.36--187.64     1.63
  1                         Zuclopenthixol             N05AF05    30        25.00             25.00                             0.83
  28                        Zuclopenthixol depot       N05AF05    15        9.52              11.39           10.01--12.78      0.76

The proportion of polypharmacy for every antipsychotic and the dose used when antipsychotics were used alone or in combination are showed in Tables [5](#pone.0163796.t005){ref-type="table"} and [6](#pone.0163796.t006){ref-type="table"}.

10.1371/journal.pone.0163796.t005

###### Proportion of antipsychotic polypharmacy compared with monotherapy (n = 1116).
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  Drug                       ATC code   Prescriptions N (%)   Monotherapy N (%)   Polypharmacy N (%)
  -------------------------- ---------- --------------------- ------------------- --------------------
  Amisulpride                N05AL05    47 (3.2%)             19 (40%)            28 (60%)
  Aripiprazole               N05AX12    262 (17.6%)           181 (69%)           81 (31%)
  Asenapine                  N05AH05    88 (5.9%)             59 (67%)            29 (33%)
  Chlorpromazine             N05AA01    3 (0.2%)              1 (33%)             2 (67%)
  Clotiapine                 N05AH06    24 (1.6%)             5 (21%)             19 (79%)
  Clozapine                  N05AH02    65 (4,4%)             22(34%)             43 (66%)
  Fluphenazine               N05AB02    16 (1.1%)             5 (31%)             11 (69%)
  Haloperidol                N05AD01    25 (1.7%)             11 (44%)            14 (56%)
  Levomepromazine            N05AA01    13 (0.9%)             10 (77%)            3 (23%)
  Levosulpiride              N05AL07    1 (0.1%)              0                   1 (100%)
  Olanzapine                 N05AH03    150 (10.0%)           102 (68%)           48 (32%)
  Paliperidone               N05AX13    104 (7%)              63 (61%)            41 (39%)
  Long-acting paliperidone   N05AX13    214 (14.4)            118 (55%)           96 (45%)
  Perphenazine               N05AB03    1 (0.1%)              1 (100%)            0
  Pimozide                   N05AG02    3 (0.2%)              2 (67%)             1 (33%)
  Quetiapine                 N05AH04    279 (18.8%)           176 (63%)           103 (37%)
  Risperidone                N05AX08    110 (7.5%)            61 (55%)            49 (45%)
  Long-acting risperidone    N05AX08    5 (0.3%)              4 (80%)             1 (20%)
  Sertindole                 N05AE03    1 (0.1%)              0                   1 (100%)
  Sulpiride                  N05AL01    2 (0.1%)              2 (100%)            0
  Tiapride                   N05AL03    19 (1.3%)             15 (79%)            4 (21%)
  Ziprasidone                N05AE04    14 (0.9%)             4 (29%)             10 (71%)
  Zuclopenthixol             N05AF05    1 (0.1%)              0                   1 (100%)
  Zuclopenthixol depot       N05AF05    28 (1.9%)             5 (18%)             23 (82%)
  TOTAL                                 1475                  866 (58.7%)         609 (41%)

10.1371/journal.pone.0163796.t006

###### Antipsychotic doses when use in combination (n = 287).
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  Drug                       ATC code   One antipsychotic   Two antipsychotics   Three antipsychotics   Four antipsychotics                                   
  -------------------------- ---------- ------------------- -------------------- ---------------------- --------------------- ------------ -------- --------- --------
  Amisulpride                N05AL05    19 (2.2%)           315.79               22 (4.5%)              665.91                5 (4.7%)     720.00   1 (10%)   200.00
  Aripiprazole               N05AX12    181 (21%)           11.01                71 (14.4%)             16.48                 9 (8.4%)     17.22    1 (10%)   25.00
  Asenapine                  N05AH05    59 (6.8%)           8.01                 23 (4.7%)              12.61                 6 (5.6%)     9.17     0 (0%)    
  Chlorpromazine             N05AA01    1 (0.1%)            30.00                0 (0%)                                       2 (1.9%)     100.00   0 (0%)    
  Clotiapine                 N05AH06    5 (0.6%)            34.00                13 (2.6%)              35.38                 5 (4.7%)     48.00    1 (10%)   20.00
  Clozapine                  N05AH02    22 (2.5%)           248.64               40 (8.13%)             307.13                3 (2.8%)     320.00   0 (0%)    
  Fluphenazine               N05AB02    5 (0.6%)            0.63                 8 (1.62%)              1.05                  3 (2.8%)     0.89     0 (0%)    
  Haloperidol                N05AD01    11 (1.3%)           3.75                 11 (2.2%)              9.34                  2 (1.9%)     12.50    1 (10%)   5.00
  Levomepromazine            N05AA01    10 (1.2%)           76.00                2 (0.4%)               100.00                1 (0.9%)     100.00   0 (0%)    
  Levosulpiride              N05AL07    0 (0%)                                   1 (0.2%)               25.00                 0 (0%)                0 (0%)    
  Olanzapine                 N05AH03    102 (11.8)          8.97                 37 (7.5%)              11.96                 10 (9.3%)    11.00    1 (10%)   5,00
  Paliperidone               N05AX13    63 (7.3%)           6.57                 31 (6.3%)              8.81                  9 (8.4%)     10.67    1 (10%)   3.00
  Long-acting paliperidone   N05AX13    118 (13.6%)         4.00                 81 (16.5%)             4.81                  15 (14%)     5.48     0 (0%)    
  Perphenazine               N05AB03    1 (0.1%)            8.00                 0 (0%)                                       0 (0%)                0 (0%)    
  Pimozide                   N05AG02    2 (0.23%)           2.50                 1 (0.2%)               6.00                  0 (0%)                0 (0%)    
  Quetiapine                 N05AH04    176 (20.3%)         158.45               79 (16.1%)             244.78                21 (19.6%)   309.52   3 (30%)   166.66
  Risperidone                N05AX08    61 (7.0%)           3.12                 41 (8.3%°              5.30                  7 (6.5%)     6.50     1 (10%)   3.00
  Long-acting risperidone    N05AX08    4 (0.5%)            3.57                 1 (0.2%)               3.57                  0 (0%)                0 (0%)    
  Sertindole                 N05AE03    0 (0%)                                   1 (0.2%)               4.00                  0 (0%)                0 (0%)    
  Sulpiride                  N05AL01    2 (0.2%)            100.00               0 (0%)                                       0 (0%)                0 (0%)    
  Tiapride                   N05AL03    15 (1.7%)           140.00               3 (0.6%)               150.00                1 (0.9%)     200.00   0 (0%)    
  Ziprasidone                N05AE04    4 (0.5%)            65.00                7 (1.4%)               165.71                3 (2.8%)     133.33   0 (0%)    
  Zuclopenthixol             N05AF05    0 (0%)                                   1 (0.2%)               25.00                 0 (0%)                0 (0%)    
  Zuclopenthixol depot       N05AF05    5 (0.6%)            9.52                 18 (3.7%)              11.90                 5 (4.7%)     11.43    0 (0%)    
  TOTAL                                 866                                      492                                          107                   10        

Discussion {#sec016}
==========

Main findings {#sec017}
-------------

In this study, we described a method to perform naturalistic prospective data gathering regarding prescription habits via a web-based application available from a smartphone or any other Internet-connected wireless device. This observational study was the first step of the development of CDSS that may help care providers to better monitor their prescriptions. We found that antipsychotics were mostly used in schizophrenia and related disorders but also in other disorders, in both approved and off label indications. Antipsychotic polypharmacy was employed in 26% of prescriptions made. Second-generation antipsychotics were mainly chosen for prescriptions (quetiapine, aripiprazole and long-acting paliperidone). Excessive dosing was only found with long acting paliperidone and ziprasidone whereas the use of low doses was relatively common. In this study, we were able to identify polypharmacy high dose and off label use in an outpatient setting. These results provide information about drug management under real conditions and highlight discrepancies between guidelines and actual practice that could guide research in new uses for drugs.

Limitations {#sec018}
-----------

The current study was performed in a naturalistic setting of patients treated as usual. Out of the 4975 outpatients that received psychiatric care during study period, 4345 agreed to participate to the study. It is likely that some patients were not asked to participate due to the supplementary burden of entering data into the MEmind web application. Furthermore, some patients did not meet the inclusion criteria or refused to participate. During the preliminary process of the study, clinicians pointed out that the monitoring of patient acceptability, including refusal and reason for refusal or agreement, would add an additional task to fulfill during the consultation. This could have altered the naturalistic setting required for the study. Another concern of clinicians was also that this monitoring would have provided information about individual performance toward recruitment process. For these reasons, patients not meeting the inclusion criteria, patients who were not asked to participate, and patients refusing to participate were considered to be "missing data". Overall, 4345 were finally included in the final analysis. Thus, data were partially or totally missing for 630 patients (12%) that were not included in the final analysis.

Type of antipsychotics used {#sec019}
---------------------------

In our practice, second-generation antipsychotics were more commonly used than classic antipsychotics, with quetiapine, aripiprazole and long-acting paliperidone representing the most prescribed antipsychotics. This prescription habit reflects how second-generation antipsychotics have become the first-line of treatment for schizophrenia because of their fewer extrapyramidal side effects \[[@pone.0163796.ref028]--[@pone.0163796.ref030]\].

The prevalent use of quetiapine reflects our outpatient setting with anxiety and mood disorders being the more frequent disorders. This also suggests greater approval and off label use of quetiapine in recent years \[[@pone.0163796.ref030]\]. In this way, quetiapine could be used for generalized anxiety disorder \[[@pone.0163796.ref031]\], depression \[[@pone.0163796.ref032],[@pone.0163796.ref033]\], insomnia \[[@pone.0163796.ref034]\] or dementia-related psychiatric symptoms \[[@pone.0163796.ref030],[@pone.0163796.ref035]\].

Range of diagnoses where antipsychotics were used and off label use {#sec020}
-------------------------------------------------------------------

Consistent with findings in Spain \[[@pone.0163796.ref036]\], in our sample, around half of antipsychotic prescriptions were made in schizophrenia and related disorders while the rest were in other diagnoses. We also found that antipsychotics were prevalently utilized for mood disorders, personality disorders and, anxiety and related disorders (F40-F49 IDC codes) with more than 50% of prescriptions used in these three categories. As mood disorders include bipolar disorder, antipsychotic use is logical and expected. It is also important to remember approved and evidence based use of second generation antipsychotics in treatment-resistant depression (29,30). For anxiety and personality disorders, mainly represented by borderline personality disorder, antipsychotic use is not approved but widespread, with evidence based results on the topic \[[@pone.0163796.ref037],[@pone.0163796.ref038]\]. A minority use of antipsychotics in our sample was made by participants with substance use disorders, mental retardation or ICD codes between F0 and F09 which includes dementia. These are uses consistent with those previously reported \[[@pone.0163796.ref039],[@pone.0163796.ref040]\]. Patients with schizophrenia that did not have antipsychotic medication were patients in a change in treatment process (wash out period).

Considering the prevalent use of antipsychotics, it is interesting to reflect on how within complex situations, or even just daily clinical practice, solutions may be required that sometimes do not fit guidelines. Additionally, it is common in psychiatric practice to treat symptoms against diseases using the pharmacodynamic properties of drugs in order to guide treatment \[[@pone.0163796.ref041]\].

Antypsychotic polipharmacy {#sec021}
--------------------------

The 26% rate of antipsychotic polypharmacy found in our sample is consistent with rates in outpatient settings worldwide \[[@pone.0163796.ref009],[@pone.0163796.ref011],[@pone.0163796.ref012]\] and in Spain \[[@pone.0163796.ref042],[@pone.0163796.ref043]\]. Guidelines accepted antipsychotic polypharmacy in cases of cross-titration, control of acute disturbances and clozapine augmentation \[[@pone.0163796.ref044],[@pone.0163796.ref045]\]. As our study is a transversal observation of our sample, we cannot measure cases of cross-titration. Acute disturbances are more likely treated in an inpatient setting, so that is not a plausible explanation for our rates of polypharmacy. Concerning clozapine augmentation, we used this antipsychotic in polypharmacy in 66% of cases, but this still does not explain all the polypharmacy employed.

Interestingly, classic long acting antipsychotics were mostly used in polypharmacy, 82% of prescriptions of zuclopenthixol depot and 69% of fluphenazine, which may reflect a frequent and non-evidence based clinical practice in patients with chronic schizophrenia course \[[@pone.0163796.ref046]\].

Clotiapine is another classic antipsychotic more frequently used in combination (79% of prescriptions). This high rate of polypharmacy and the low dosage generally used of this drug (PDD/DDD = 0.47) probably highlights its use for its hypnotic properties rather than as an antipsychotic. Clotiapine is an antipsychotic with a rapid onset of action and a strong sedative effect, which explains its use in insomnia in psychotic and non-psychotic patients \[[@pone.0163796.ref047]\].

Finally, amisulpride is also used in combination (68%) more frequently than in monotherapy. It is commonly said that for amisulpride, polypharmacy is the rule rather than the exception \[[@pone.0163796.ref048]\]. Moreover, amisulpride may be particularly suitable for clozapine augmentation \[[@pone.0163796.ref049]\]. This is a probable use in our sample according to our data.

Antipsychotics dosing {#sec022}
---------------------

According to our results, only two antipsychotics were employed at excessive dosing: long-acting paliperidone (PDD/DDD = 1.76) and ziprasidone (PDD/DDD = 1.63). This finding is consistent with previous knowledge; high doses are prevalent in hospitalized patients with schizophrenia \[[@pone.0163796.ref050],[@pone.0163796.ref051]\] and less frequent in outpatient settings \[[@pone.0163796.ref052]\].

On the other hand, many antipsychotics were also used at low doses. This dosage use could be explained by the outpatient setting, where patients usually are in an established moment of the illness. Furthermore, antipsychotics are used in conditions other than psychosis, like insomnia in the case of clotiapine, chlorpromazine or levomepromazine, or mood and anxiety disorders or behaviour disorders in dementia, in the case of quetiapine. Special mention is needed for asenapine, an antipsychotic approved in Spain only for manic episodes in bipolar disorder. This narrow indication probably reflects its low dose usage.

Information for this study was obtained with a novel web tool, the mental state tracker MEmind. This device also has an interesting potential use in clinical research. Data collected by the provider are instantaneously transmitted to the database and made available for data mining. The system is also able to deliver alarms. In this pilot study we only made both raw data and graphic information about medical prescription available for the provider. We are currently assessing the possibility of incorporating, in the analysis, data proceeding directly from the patient that uses the EMA function of the program.

Future development and implementation {#sec023}
-------------------------------------

In this study, treatment related information was collected via the web-application but processed secondarily by statistical software. As a result, it would have been possible to give instantaneous feedback to the care provider. Programs also exist that are able to alarm care providers about treatment interaction \[[@pone.0163796.ref053]\]. However, for the first step of the development of our web application, we decided to only monitor prescription habits and disable momentary feedback about treatment and alarm function of our web application. Alarms and feedback are part of the decision making support process \[[@pone.0163796.ref054]\]. By enabling this function in our web application, we probably would have faced the professional reluctance to welcome our web application in a routine clinical setting. Many studies have encountered difficulties incorporating EHRs into routine practices, especially when associated with CDSS. We are currently assessing professional acceptability of the device in order to propose a CDSS to clinicians that could be easily incorporated in their practice. Evaluating changes in routine practice caused by the use of the Memind application would also be an objective.

The objective of this study was to describe the prescription habits of antipsychotics via the Memind web-application. The Memind web application has Patient interface but this feature was not enabled for the present study. As a result patient acceptability of the application was not assessed, and neither was treatment adherence or symptom tracking using the EMA function. EMA involves repeated sampling of subjects' behaviors and experiences in real time, in their natural environment. EMA has been successfully used for real-time self-reporting of symptoms and behaviours. This feature will soon allow us to integrate data proceeding from patient self-monitoring into CDSS.

Although many EHR CDSS have yet to be developed, their performance varies largely. Approaches that foster the impact of CDSS often rely on improved alerting concerning evidence-based recommendation or drug-drug interaction. We also believe that alerting could be taken into account by implementing or refining a severity grading. For this very first step of development, we only focused on the capacity of the web application to monitor prescription \[[@pone.0163796.ref055]\]. However, smartphone technology gives us the opportunity to combine pharmacological insight into analysis with idiosyncratic clinical data proceeding either from medical assessment or patient. A promising challenge would be to further incorporate an alert algorithm into a clinical dimension, for example integrating it into EMA data \[[@pone.0163796.ref056]\].
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